Recurrent C. diff: Using Real-World Data to Guide Treatment Strategies

In honor of C. diff Awareness Month, the IDSA Foundation invites you to join a webinar that will provide the latest insights on recurrent Clostridioides difficile infection. This session will highlight real-world outcomes from newly approved gut microbial therapies and offer a comprehensive look at the ongoing challenges posed by C. diff, recognized as one of the top five most urgent public health threats. With nearly 500,000 cases annually in the U.S. and up to 29,000 associated deaths, rCDI poses a critical risk, particularly with recurrence rates reaching 30% after an initial infection. The widespread use of antibiotics further increases this risk. Our specialists will discuss the current landscape of C. diff infections and explore innovative approaches to reduce recurrence, focusing on the benefits of GMT. This webinar will offer the opportunity for health care professionals to further their understanding of the epidemiology, treatment advancements and patient care considerations surrounding rCDI. Learning Objectives: • Discuss the epidemiology of rCDI, including the population at most risk and the risk presented by antibiotics; • Review the current incidence rates, mortality rates, hospital quality metrics and medical costs of rCDI in the United States; • Describe the physiologic role of the microbiome and the need to address dysbiosis in rCDI; • Evaluate the evidence for GMT treatment using real-world evidence and provide patient educational points upon discharge to prevent spread of C. diff and reduce occurrences of rCDI; • Identify strategies to incorporate current evidence and best practices for managing rCDI into clinical practice, focusing on the healthcare team’s role in reducing incidence; • Discuss the impact of rCDI on patient quality of life and hear from a patient treated for rCDI.